Antibiotic resistance in neonates in China 2012-2019: A multicenter study

J Microbiol Immunol Infect. 2022 Jun;55(3):454-462. doi: 10.1016/j.jmii.2021.05.004. Epub 2021 May 15.

Abstract

Background: To investigate antibiotic resistance of pathogens responsible for neonatal invasive bacterial infections (IBIs) in China.

Methods: Cross-sectional study of neonates with IBI evaluated in nine hospitals in China (January 2012-August 2019). Antibiotic resistance patterns of pathogens responsible for neonatal IBIs were analyzed.

Results: Of 3770 full-term neonates who were subjected to lumbar puncture and a blood culture, IBIs were diagnosed in 460 neonates (12.2%). Escherichia coli and Group B Streptococcus (GBS) were the leading pathogens, followed by Enterococcus spp, and Staphylococcus aureus. E. coli expressed high resistance to ampicillin (72.0%) and third-generation cephalosporins (cefotaxime, 34.8%; ceftriaxone, 38.1%). The prevalence of extended spectrum beta-lactamase (ESBL)-producing E. coli was 34.1%. The proportions of E. spp resistant to penicillin and ampicillin were 60% and 54.1%. All S. aureus showed resistance to ampicillin and penicillin. The resistance rate of S. aureus to methicillin was 50%. Although all GBS were susceptible to penicillin and ampicillin, the proportions of GBS resistant to erythromycin and clindamycin were 75.9% and 77.3%. Antibiotic susceptibility appeared to improve in 2019. Susceptibility of E. coli to ampicillin, cefotaxime, and ceftriaxone improved to 42.9%, 76.9%, and 71.4% in 2019, compared with 12.5%, 37.5%, and 50% in 2012. The prevalence of ESBL-producing E. coli declined to 20% in 2019, lower than 100% in 2012. Susceptibility of GBS to erythromycin and clindamycin improved from 0% in 2012 to 28.6% and 25% in 2019.

Conclusions: The prevalence of antibiotic resistance is high in neonates in China, although there is a favorable declining trend in recent years.

Keywords: Antibiotic resistance; China; Invasive bacterial infections(IBIs); Neonate.

Publication types

  • Multicenter Study

MeSH terms

  • Ampicillin / pharmacology
  • Ampicillin / therapeutic use
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Cefotaxime
  • Ceftriaxone*
  • China / epidemiology
  • Clindamycin*
  • Cross-Sectional Studies
  • Drug Resistance, Bacterial
  • Drug Resistance, Microbial
  • Erythromycin
  • Escherichia coli
  • Humans
  • Infant, Newborn
  • Microbial Sensitivity Tests
  • Penicillins
  • Staphylococcus aureus
  • Streptococcus agalactiae

Substances

  • Anti-Bacterial Agents
  • Penicillins
  • Clindamycin
  • Erythromycin
  • Ceftriaxone
  • Ampicillin
  • Cefotaxime